A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma

Background and aims Pancreatic adenocarcinoma (PAAD) is highly aggressive and characterized by a poor prognosis. Oxidative stress has great impacts on the occurrence and development of tumors. However, the predictive role of oxidative stress related genes on PAAD patients’ prognosis remains unclear. In this study, we aimed to construct a prognostic model for PAAD based on oxidative stress genes and to evaluate its predictive value. Methods The Cancer Genome Atlas (TCGA) and three Gene Expression Omnibus (GEO) datasets were used to identify differentially expressed oxidative stress genes. Univariate Cox regression, Kaplan-Meier and multivariate Cox regression analysis were used to select genes and to construct a prognosis model. According to the median value of the model’s risk score, patients were divided into high and low risk groups, and gene set enrichment analysis (GSEA), immune infiltration and immunotherapy effect, drug resistance and the expression of immune checkpoint related genes and synthetic driver genes of T cell proliferation were analyzed. Finally, the mRNA and protein levels of four genes in PAAD were verified by the clinical proteomic tumor analysis consortium (CPTAC) database and the immunostaining of patients’ tissue. Results 55 differentially expressed oxidative stress genes were identified, and four genes including MET, FYN, CTTN and CDK1 were selected to construct a prognosis model. GESA indicated that immune related pathways, metabolic pathways and DNA repair pathways were significantly enriched in the high risk group as compared to the low risk group. The frequency of genetic mutations was also significantly higher in high risk groups than that in low risk groups. Moreover, the infiltration level of 23 immune cells as well as the expression of immune checkpoint related and synthetic driver genes of T cell proliferation were significantly altered, with the better immunotherapy effect occurring in low risk group. In patient PAAD tissues, the mRNA and protein levels of these four genes were up-regulated. Conclusion We have successfully constructed a four oxidative stress gene prognostic model that has important predictive value for PAAD patients, and this model might be a promising guidance for prognostic prediction and efficacy monitoring in clinical individualized therapy.

[1]  Yuanyu Huang,et al.  Conscription of Immune Cells by Light‐Activatable Silencing NK‐Derived Exosome (LASNEO) for Synergetic Tumor Eradication , 2022, Advanced science.

[2]  E. Nice,et al.  Redox signaling at the crossroads of human health and disease , 2022, MedComm.

[3]  Neville E. Sanjana,et al.  A genome-scale screen for synthetic drivers of T cell proliferation , 2022, Nature.

[4]  Zhe Zhang,et al.  The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role , 2022, Molecular cancer.

[5]  Md Jamal Uddin,et al.  CO-Releasing Molecule-2 Prevents Acute Kidney Injury through Suppression of ROS-Fyn-ER Stress Signaling in Mouse Model , 2021, Oxidative medicine and cellular longevity.

[6]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[7]  S. Cook,et al.  CDK1, the Other 'Master Regulator' of Autophagy. , 2020, Trends in cell biology.

[8]  J. Galon,et al.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.

[9]  Charles R. Thomas,et al.  Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma , 2020, CA: a cancer journal for clinicians.

[10]  P. Jänne,et al.  Targeting MET Dysregulation in Cancer. , 2020, Cancer discovery.

[11]  A. Drilon,et al.  MET-dependent solid tumours — molecular diagnosis and targeted therapy , 2020, Nature Reviews Clinical Oncology.

[12]  Myung Ah Lee,et al.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[13]  A. Voors,et al.  Treating oxidative stress in heart failure: past, present and future , 2018, European journal of heart failure.

[14]  P. Ramos-García,et al.  An update of knowledge on cortactin as a metastatic driver and potential therapeutic target in oral squamous cell carcinoma. , 2018, Oral diseases.

[15]  Ga Young Lee,et al.  The Role of Vitamin E in Immunity , 2018, Nutrients.

[16]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[17]  L. Trusolino,et al.  Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy , 2018, Nature Reviews Cancer.

[18]  T. Śliwiński,et al.  The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  J. García-Foncillas,et al.  Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment , 2017, Journal of clinical medicine.

[20]  J. Sadoshima,et al.  Tyrosine kinase FYN negatively regulates NOX4 in cardiac remodeling. , 2016, The Journal of clinical investigation.

[21]  Pornpimol Charoentong,et al.  Computational genomics tools for dissecting tumour–immune cell interactions , 2016, Nature Reviews Genetics.

[22]  Yi-long Wu,et al.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy , 2016, Tumor Biology.

[23]  S. Bhattacharyya,et al.  Tumour, Oxidative Stress and Host T Cell Response: Cementing the Dominance , 2015, Scandinavian journal of immunology.

[24]  H. Ditzel,et al.  Fyn is an important molecule in cancer pathogenesis and drug resistance. , 2015, Pharmacological research.

[25]  Jin Tan,et al.  ROS and Autophagy: Interactions and Molecular Regulatory Mechanisms , 2015, Cellular and Molecular Neurobiology.

[26]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[27]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[28]  H. Sies,et al.  Oxidative stress: a concept in redox biology and medicine , 2015, Redox biology.

[29]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[30]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[31]  R. Quarto,et al.  Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages , 2014, Haematologica.

[32]  Hyeyoung Kim,et al.  Oxidative Stress and Cytokines in the Pathogenesis of Pancreatic Cancer , 2014, Journal of cancer prevention.

[33]  T. Mak,et al.  Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.

[34]  T. Moliné,et al.  Oxidative stress and cancer: An overview , 2013, Ageing Research Reviews.

[35]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[36]  F. Musumeci,et al.  Fyn kinase in brain diseases and cancer: the search for inhibitors. , 2011, Current medicinal chemistry.

[37]  B. Aggarwal,et al.  Oxidative stress, inflammation, and cancer: how are they linked? , 2010, Free radical biology & medicine.

[38]  R. Salgia,et al.  Fyn: a novel molecular target in cancer. , 2010, Cancer.

[39]  R. Salgia,et al.  Fyn: a novel molecular target in prostate cancer , 2010 .

[40]  Q. Zhan,et al.  Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3–CTTN–Akt pathway in esophageal squamous cell carcinoma , 2009, Oncogene.

[41]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[42]  D. Grieco,et al.  New insights on oxidative stress in cancer. , 2009, Current opinion in drug discovery & development.

[43]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[44]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Y. Rojanasakul,et al.  Inflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[46]  Q. Zhan,et al.  Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. , 2006, Cancer research.

[47]  J. K. Lee,et al.  Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[48]  A. Rustgi,et al.  Mutant KRAS in the initiation of pancreatic cancer. , 2005, Biochimica et biophysica acta.

[49]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Bicknell,et al.  Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer , 2001, Breast Cancer Research.

[51]  T. van Dyke,et al.  Dietary antioxidant depletion: enhancement of tumor apoptosis and inhibition of brain tumor growth in transgenic mice. , 2000, Carcinogenesis.